Interpretations of the NCCN guidelines for breast cancer risk reduction (version 2023)
- VernacularTitle:2023年《NCCN乳腺癌风险降低指南》解读
- Author:
Xinyi GUO
1
,
2
;
Qing LV
1
,
2
Author Information
1. 1. Division of Breast Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
2. 2. Breast Center, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Breast cancer;
risk assessment;
risk reduction;
NCCN guidelines;
interpretation of guidelines
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(06):787-804
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer, the most common malignancy in the world, also causes the most death cases of women among malignancies. Breast cancer risk reduction guidelines (version 2023) was updated by National Comprehensive Cancer Network (NCCN). Based on high-level evidences from evidence-based medicine and the latest research progress, the guidelines provided standardized guidance for breast cancer risk assessment and risk reduction strategies for individuals without a history of invasive breast cancer or ductal carcinoma in situ, which has attracted widespread attention from clinicians worldwide. Breast cancer is also the most common malignancy in Chinese women, and the number of newly diagnosed breast cancer cases each year in China ranks first in the world due to the large population, so the breast cancer prevention has become a major public health challenge in China. Aimed to provide reference for breast cancer prevention in China, this article interpreted the guidelines (the new version) based on the characteristics of breast structure in Asian women and the epidemiological characteristics of breast cancer in China.
